Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|January 15, 2026
Informative censoring in maintenance therapy trials for advanced ovarian cancer: An empirical assessment of its impact on treatment benefitRachel Woodford, Sally Lord, Annelise Decaria, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2012
Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimusChee Khoon Lee, Ian C Marschner, R John Simes, et al.
Therapeutic Advances in Medical Oncology|August 11, 2018
Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysisKatrin M Sjoquist, Sarah J Lord, Michael L Friedlander, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 19, 2018
Biosimilarity and Interchangeability: Principles and Evidence: A Systematic ReviewRoss A McKinnon, Matthew Cook, Winston Liauw, et al.
BMJ Medicine|September 22, 2023
Transparent reporting of adaptive clinical trials using concurrently randomised cohortsIan C Marschner, Mark Jones, James A Totterdell, et al.
Cancer|January 28, 2022
Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancerAngelina Tjokrowidjaja, Sarah J Lord, Thomas John, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2024
Challenges of estimating treatment effects after a positive interim analysisYu Yang Soon, Ian C Marschner, Manjula Schou, et al.
The Journal of Pediatrics|October 14, 2018
Pulse Oximeter Saturation Targeting and Oximeter Changes in the Benefits of Oxygen Saturation Targeting (BOOST)-II Australia and BOOST-II UK Oxygen TrialsBenjamin J Stenson, Mark Donoghoe, Peter Brocklehurst, et al.
JAMA Network Open|September 17, 2024
Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate CancerYu Yang Soon, Ian C Marschner, Manjula Schou, et al.
Cancer|January 5, 2022
The validity of progression-free survival 2 as a surrogate trial end point for overall survivalRachel G Woodford, Deborah D-X Zhou, Peey-Sei Kok, et al.
Pageof 6